| Purity: | >99% |
|---|---|
| Brand Name: | NJBN STEROID |
| Grade Standard: | |
| Type: | |
| CAS No.: | 461432-26-8 |
| Model Number: | 461432-26-8 |
| Place of Origin: | China (Mainland) |
| EINECS No.: | 200-035-3 |
| MF: | C32H36ClNO8 |
| Other Names: | Dapagliflozin |
| Classification: | High Purity Reagents |
| Standard: | Standard |
| Usage: | An unducer of ovulation. A gonad-stimulating principle,Synthetic estrogen agonist antagonist. Gonad-stimulating principle) |
| Delivery: | Express courier |
Quick Details
Specifications
Hyperglycemia Diabetes drugs Dapagliflozin CAS 461432-26-8
Product Name:Dapagliflozin
Synonyms:DAPAGLIFLOZIN;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol;2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol;Bms 512148;D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-;Dapagliflozin(BMS-512148);(2S,4R,5R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxyMethyl)tetrahydro-2H-pyran-3,4,5-triol;1-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-deoxy-beta-D-glucopyranose (1S)-1,5-Anhydro-1-C-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxyMethyl)tetrahydro-2H-pyran-3,4,5-triol
CAS:461432-26-8
MF:C21H25ClO6
MW:408.875
Product Categories:APIs;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Other APIs;Inhibitors
Density: 1.349
Chemical Properties: White Solid
Uses: therapeutic for diabetes I or II, and hyperglycemia.
Uses: A sodium-glucose transporter 2 inhibitor.
Diabetes drugs
Dapagliflozin is a new antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca, being approved by the European Medicines Agency (EMA) on November 12, 2012. It is also the first approved SGLT2 inhibitor for the treatment of type II diabetes, being an important option in the treatment of diabetes, and is used to improve glycemic control as an adjunct to dietary and exercise for adults with type II diabetes.
Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor. on January 8, 2014, the US Food and Drug Administration (FDA) have approved it for being used in the treatment of type II diabetes. Meanwhile, FDA requires the producers to conduct post-marketing research on drug-related risks.
the post-marketing trial requested by the FDA includes a cardiovascular outcome trial for assessing the cardiovascular risk for high-risk patients after treatment with dapagliflozin at baseline and a study to assess the risk of bladder cancer in recruited patients. Another study will assess the bladder tumor-promoting effect of this drug on rodent animals. Two studies will assess the pharmacokinetics, efficacy and safety of dapagliflozin in pediatric patients; a set of strengthened pharmacovigilance program will monitor liver abnormalities and pregnancy outcome reports in patients receiving daglitazone.
